Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Bioorg Chem. 2018 Dec;81:630-641. doi: 10.1016/j.bioorg.2018.09.015. Epub 2018 Sep 8.
Novel N-(benzothiazol/oxazol-2-yl)-2-[(5-(phenoxymethyl)-4-aryl-4H-1,2,4-triazol-3-yl)thio] acetamide derivatives (5a-n) were synthesized and investigated for in vitro anti-inflammatory activity and p38α MAP kinase inhibition. Compounds showing good in vitro activities (5a, 5b, 5d, 5e, 5i, 5k and 5l) were studied for their in vivo anti-inflammatory activity using carrageenan induced rat paw edema model. Compound 5b emerged as the most active compound with an edema inhibition of 84.43%. It also showed improved GI safety profile with lower ulcer severity index and lipid peroxidation potential. Also, p38α MAP kinase assay of 5b showed superior inhibitory potency (IC:0.031 ± 0.14 µM) than the standard SB 203580 (IC:0.043 ± 0.14 µM). To predict their binding mode compounds were also docked against p38α MAP kinase enzyme. Compound 5b and SB 203580 showed hinge region interaction with MET 109.
新型 N-(苯并噻唑/恶唑-2-基)-2-[(5-(苯氧甲基)-4-芳基-4H-1,2,4-三唑-3-基)硫代]乙酰胺衍生物(5a-n)被合成并研究其体外抗炎活性和 p38α MAP 激酶抑制作用。显示出良好体外活性的化合物(5a、5b、5d、5e、5i、5k 和 5l)在角叉菜胶诱导的大鼠足肿胀模型中研究了其体内抗炎活性。化合物 5b 表现出最活跃的活性,其水肿抑制率为 84.43%。它还表现出改善的 GI 安全性特征,具有较低的溃疡严重指数和脂质过氧化潜力。此外,5b 的 p38α MAP 激酶测定显示出优于标准 SB 203580 的抑制效力(IC:0.031±0.14µM)。为了预测它们的结合模式,还将化合物对接至 p38α MAP 激酶酶。化合物 5b 和 SB 203580 与 MET 109 表现出铰链区域相互作用。